Both doses (50 µg and 100 µg) of the COVID-19 vaccine made by Moderna meet the safety requirements to be administered to the population, Public Health Strategic Interventions Director-General at the
Ministry of Health (Minsa) Alexis Holguin said on Sunday.
"These vaccines, at the 50 µg and 100 µg dose levels, have passed the safety and efficacy criteria. They are safe vaccines," Holguin stated.
His remarks were delivered at a press conference held by a group of experts from Minsa this afternoon after complaints about an alleged administration of Moderna vaccine doses containing more than the allowed amount of the vaccine.
He explained that health regulations in Peru allow administering both 50 µg and 100 µg of this vaccine. In the case of the third or fourth doses, 100 µg are administered to immunosuppressed patients, while 50 µg are administered in other cases.
In this regard, Holguin noted that cases of reactions such as pain in the area of inoculation, headache, and fever have been reported during the administration of the fourth dose of the Moderna vaccine.
"That is why a new meeting (of the group of experts) is being held to specify the amount of this type of medication in the fourth dose that is being administered," he emphasized.
The official commented that in different countries, such as the United States and Canada, changes have been made such as administering 100 µg of the Moderna vaccine to specific populations, which are much more exposed to COVID-19, such as health staff.
For her part, Minsa's Immunizations Director Maria Elena Martinez reported that the Moderna COVID-19 vaccine will continue to be administered to those over 70 years of age, health personnel, and immunosuppressed people, but at a 50 µg dose level.
(END) LIT/RMB
Published: 4/24/2022